Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

Although US stocks closed slightly higher on Friday, there were a few notable insider trades.

Fate Therapeutics Earnings Preview ↗

May 02, 2023

Via Benzinga

$1.7M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying ↗

April 24, 2023

Via Benzinga

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results

April 24, 2023

FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action – FATE

15 Analysts Have This to Say About Fate Therapeutics ↗

March 27, 2023

Via Benzinga

Expert Ratings for Fate Therapeutics ↗

March 01, 2023

Via Benzinga

March 22, 2023

From The Rosen Law Firm, P.A.

FATE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc. and Encourages Investors to Contact the Firm

March 21, 2023

From Bragar Eagel & Squire, P.C.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)

March 21, 2023

From The Law Offices of Frank R. Cruz

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE

March 19, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm

Topics Lawsuit

March 17, 2023

ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE

March 13, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NASDAQ:FATE Investor Notice: Deadline on March 22, 2023 in Lawsuit Against Fate Therapeutics, Inc ↗

Topics Lawsuit

March 13, 2023

San Diego, CA -- (SBWIRE) -- 03/13/2023 -- The Shareholders Foundation announced that a deadline is coming up on March 22, 2023 in the lawsuit filed for certain investors of Fate Therapeutics, Inc....

Via SBWire

Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fate Therapeutics, Inc. (FATE) Investors of Class Action and Last Few Days to Actively Participate

March 13, 2023

From Bronstein, Gewirtz & Grossman, LLC

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm

March 12, 2023

ROSEN, A LEADING NATIONAL FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE

March 09, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IBM, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm

Topics Lawsuit

March 06, 2023

ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FATE

March 06, 2023

From The Rosen Law Firm PA

Fate Therapeutics to Present at Upcoming March Investor Conferences

March 03, 2023

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FATE

March 03, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm

Topics Lawsuit

March 01, 2023

Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

February 28, 2023

FATE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FATE

February 28, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm

Topics Lawsuit

February 24, 2023

ROSEN, A GLOBAL AND LEADING FIRM, Encourages Fate Therapeutics, Inc. Investors with Loses to Secure Counsel Before Important Deadline in Securities Class Action - FATE

February 21, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IBM, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm

Topics Lawsuit

February 19, 2023

ROSEN, A RANKED AND LEADING FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE

February 16, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FATE

Topics Lawsuit

February 14, 2023

From Pomerantz LLP

Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

February 14, 2023

Don’t forget to check out our premarket coverage here Fate Therapeutics, Inc. (NASDAQ: FATE) fell 4.1% to $6.13 in pre-market trading. Fate Therapeutics is expected to report Q4 results on Tuesday,...

Via Benzinga

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm

February 13, 2023